UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation. The world is changing and it’s no different for the ...

UCB Pharma has announced that Exemed Pharmaceuticals, a fast-growing Indian manufacturing company, will acquire UCB’S Indian production facility in Vapi. The deal includes a multi-year supply ...

Belgian pharmaceutical company UCB is dropping its development of minzasolmin in patients with Parkinson's' disease after the ORCHESTRA study failed to meet its primary and secondary endpoints.

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various factors.

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...

Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

CBC Group, in partnership with the Mubadala Investment Company, has completed the strategic acquisition of Union Chimique Belge's (UCB) mature neurology and allergy business in China for $680m.

Belgium’s largest drugmaker UCB today released long-term data from the BE HEARD^ trials for Bimzelx (bimekizumab) in moderate ...